Therapy Optimization in Multiple Sclerosis (MS)

• Status: Completed
• Trial end date: 2013-01-01

Summary

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Details

• Lead Sponsor: Teva Neuroscience, Inc.
• Treatments: (T,G)-A-L; Glatiramer Acetate; Interferon beta-1b; Interferon-beta